secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001711279-22-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q2 net loss widens to $28.1M; BLA filed for B-VEC, KB407 IND accepted
--------------------------------------------------------------------------------

- Q2 net loss $28.1M ($1.10/share) vs $16.4M loss YoY; cash $438.5M.
- Filed BLA for B-VEC (DEB therapy) with FDA on June 22, 2022.
- FDA accepted IND for KB407 (cystic fibrosis); Phase 1 trials expected 2H 2022.
- R&D expense $10.9M, G&A $17.9M; losses reflect increased commercial prep.
- Pipeline: KB105 dosing to resume 2H 2022; KB104 IND later 2022; KB301 Phase 2 in Q4 2022/Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000050/0001711279-22-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000050/krys-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001711279-22-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer